Description
DS-1103a is an experimental medicine being studied in clinical trials for advanced cancers, including colorectal cancer. It is being tested in combination with other cancer treatments. Specifically, in colorectal cancer trials, DS-1103a is being investigated in patients whose tumors have a HER2 mutation. This medicine is currently in Phase 1 trials, which means researchers are primarily looking at its safety and determining the best dose. The goal is to see if blocking a specific interaction on cancer cells can help the immune system fight the cancer, especially when used with other therapies like trastuzumab deruxtecan.
Mechanism of Action
DS-1103a is a type of antibody designed to block the interaction between two proteins: SIRPα (Signal-regulatory protein alpha) and CD47. CD47 is often found on the surface of cancer cells and can send signals that prevent immune cells (like macrophages) from attacking and destroying the cancer cells. By blocking the SIRPα-CD47 interaction, DS-1103a aims to remove this 'do not eat me' signal, potentially allowing the immune system to better recognize and eliminate cancer cells. It is being studied in combination with other cancer therapies to see if this approach enhances the overall treatment effect.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.